Clinical trial
An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)
Name
SimpliciTB (B-Pa-M-Z) NC-008
Description
To evaluate the efficacy, safety and tolerability at 8 weeks (2-months), 52 weeks (12-months), and 104 Weeks (24-months) post the start of the following treatment regimens in participants with: Drug Sensitive TB (DS-TB) patients given BPaMZ for 17 Weeks ( or 4 months) vs. Standard HRZE/HR treatment given for 26 weeks (or 6 months) and Drug Resistant TB (DR-TB) patients given BPaMZ for 26 Weeks (or 6 months)
Trial arms
Trial start
2018-07-30
Estimated PCD
2021-07-01
Trial end
2022-06-10
Status
Completed
Phase
Early phase I
Treatment
Pretomanid
200 mg tablets
Arms:
Drug Resistant BPaMZ, Drug Sensitive BPaMZ
Other names:
PA-824, Pa
Bedaquiline
100 mg tablets
Arms:
Drug Resistant BPaMZ, Drug Sensitive BPaMZ
Other names:
B, TMC207
Moxifloxacin
400 mg tablets
Arms:
Drug Resistant BPaMZ, Drug Sensitive BPaMZ
Other names:
M
Pyrazinamide
500 mg tablets
Arms:
Drug Resistant BPaMZ, Drug Sensitive BPaMZ
Other names:
Z
HRZE
isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets
Arms:
Drug Sensitive Standard Treatment
Other names:
isoniazid, rifampicin, ethambutol
HR
isoniazid 75 mg plus rifampicin 150 mg combination tablets
Arms:
Drug Sensitive Standard Treatment
Other names:
isoniazid, rifampicin
Size
455
Primary endpoint
Number of Participants With Culture Negative Status by 8 Weeks
Days 0-56 (8 weeks)
Eligibility criteria
Inclusion Criteria:
* Sputum positive for tubercule bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease \[IUATLD\]/WHO scale (Appendix 1) on smear microscopy) at the trial laboratory.
* Participants with one of the following pulmonary TB conditions:
DS-TB treatment arm participants should be:
* sensitive to rifampicin and isoniazid by rapid sputum based test AND
* either newly diagnosed for TB or have a history of being untreated for at least 3 years after cure from a previous episode of TB.
DR-TB treatment arm participants should be Resistant to rifampicin and/or isoniazid.
* Of non-childbearing potential or willing to practice effective methods of birth control
* Body weight (in light clothing and no shoes) ≥ 30 kg.
* Completed informed consent form
Exclusion Criteria:
* Karnofsky score \<60%
* Any risk factor for QT prolongation
* Any planned contraindicated medicines
* Resistant to fluoroquinolones (rapid, sputum-based molecular screening tests).
Any of the following lab toxicities/abnormalities:
* CD4+ count \< 100 cells/µL (HIV infected participants)
* platelets \<75,000/mm³
* creatinine \>1.5 times upper limit of normal (ULN)
* eGFR ≤ 60 mL/min
* haemoglobin \<8.0 g/dL
* serum potassium less than the lower limit of normal for the laboratory.
* GGT: greater than 3 x ULN
* AST: ≥3.0 x ULN to be excluded;
* ALT: ≥3.0 x ULN to be excluded
* ALP: ≥3.0 x ULN to be excluded
* Total bilirubin: \>1.5 x ULN to be excluded;
* Direct bilirubin: greater than 1x ULN to be excluded
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Phase 2c multi-center, open-label, partially randomized clinical trial in DS-TB and DR-TB participants', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 455, 'type': 'ACTUAL'}}
Updated at
2024-03-07
1 organization
6 products
4 indications
Organization
Global Alliance for TB Drug DevelopmentProduct
PretomanidIndication
TuberculosisIndication
PulmonaryIndication
Multidrug-resistantProduct
BedaquilineProduct
MoxifloxacinProduct
PyrazinamideProduct
HRZEProduct
HR